FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
Andreas R. Baudy(Gene Therapy Laboratory), Simon‐Peter Williams
Cited by 62
Related Papers
[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer’s disease
|European Journal of Nuclear Medicine and Molecular Imaging|2019|130